Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

. . . Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares October 08, 2024 4:01 PM EDT | Source: Cardiol Therapeutics Inc. Toronto, Ontario--(Newsfile Corp. - October 8, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce ...